13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001009258
Total reported value
$9.6B
$9.6B
123 檔
20.7%
As reported in its official Q1 2025 Form 13F filing, Deerfield Management Company, L.p.'s tracked investment portfolio stood at $9.6B with 123 total positions.
In Q1 2025, Deerfield Management Company, L.p. adopted a defensive or profit-taking posture, trimming 3 positions and completely liquidating 114 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | NUVL | Nuvalent Inc-a | Stock-Other | 25.19% | +1.37% | — | |
| 2 | VTRS | Viatris Inc | Stock-Healthcare | 4.13% | +0.13% | -0.02% | |
| 3 | IART 0.5 08-15-25Bond | Integra Lifesciences Hld | Bond | 3.38% | — | — | |
| 4 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 3.25% | -0.95% | EXIT | |
| 5 | CNC | Centene CORP | Stock-Healthcare | 3.20% | +0.99% | — | |
| 6 | OSCR | Oscar Health Inc - Class A | Stock-Healthcare | 3.06% | — | +0.05% | |
| 7 | ✓ | Merus N V | Stock-Other | 2.64% | — | +6.77% | |
| 8 | SPRY | Ars Pharmaceuticals Inc | Stock-Other | 2.61% | -0.08% | — | |
| 9 | ACCD 0.5 04-01-26Bond | Accolade Inc | Bond | 2.58% | — | — | |
| 10 | ALNY 1 09-15-27Bond | Alnylam Pharmaceuticals | Bond | 2.50% | — | — | |
| 11 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 2.32% | +2.03% | +1.81% | |
| 12 | MIRM 4 05-01-29Bond | Mirum Pharmaceuticals | Bond | 2.26% | -2.47% | EXIT | |
| 13 | AHCO | Adapthealth CORP | Stock-Other | 2.08% | -0.36% | — | |
| 14 | INDV | Indivior Pharmaceuticals, Inc. | Stock-Other | 1.99% | — | +18.96% | |
| 15 | BKD | Brookdale Senior Living Inc | Stock-Other | 1.93% | +0.07% | — | |
| 16 | ALHC | Alignment Healthcare Inc | Stock-Other | 1.68% | — | -37.47% | |
| 17 | UTHR | United Therapeutics CORP | Stock-Healthcare | 1.68% | -0.62% | — | |
| 18 | PFE | Pfizer Inc | Stock-Healthcare | 1.67% | -0.25% | — | |
| 19 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 1.66% | -0.10% | -4.88% | |
| 20 | CPRX | Catalyst Pharmaceuticals Inc | Stock-Healthcare | 1.64% | -1.15% | EXIT | |
| 21 | DVAX | Dynavax Technologies CORP | Stock-Other | 1.33% | — | -0.04% | |
| 22 | BAX | Baxter International Inc | Stock-Healthcare | 1.30% | — | — | |
| 23 | LEGN | Legend Biotech Corp-adr | Stock-Other | 1.17% | +0.81% | +12.36% | |
| 24 | BIO | Bio-rad Laboratories-a | Stock-Healthcare | 1.09% | -0.05% | +49.08% | |
| 25 | IDYA | Ideaya Biosciences Inc | Stock-Other | 1.06% | +0.46% | +19.43% | |
| 26 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 0.90% | — | — | |
| 27 | LRMR | Larimar Therapeutics Inc | Stock-Other | 0.90% | -0.76% | — | |
| 28 | EHABUSD | Enhabit Inc | Stock-Other | 0.87% | -0.79% | EXIT | |
| 29 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 0.77% | -0.06% | -0.13% | |
| 30 | BCRX | Biocryst Pharmaceuticals Inc | Stock-Other | 0.77% | -0.12% | -36.28% | |
| 31 | IRON | Disc Medicine Inc | Stock-Other | 0.77% | — | +30.28% | |
| 32 | CNMD | Conmed CORP | Stock-Other | 0.73% | — | -0.16% | |
| 33 | LNTH 2.625 12-15-27Bond | Lantheus Holdings Inc | Bond | 0.70% | — | — | |
| 34 | NVST | Envista Holdings CORP | Stock-Healthcare | 0.69% | -0.05% | +98.83% | |
| 35 | INSM | Insmed Inc | Stock-Healthcare | 0.69% | — | — | |
| 36 | EMBC | Embecta CORP | Stock-Healthcare | 0.68% | -0.17% | -16.82% | |
| 37 | CMRXEUR | Chimerix Inc | Stock-Other | 0.63% | — | — | |
| 38 | PHVS | Pharvaris N.V. | Stock-Other | 0.63% | +0.18% | — | |
| 39 | CGEM | Cullinan Therapeutics Inc | Stock-Other | 0.58% | -0.06% | EXIT | |
| 40 | INMD | InMode Ltd. | Stock-Other | 0.55% | — | — | |
| 41 | PHR | Phreesia Inc | Stock-Other | 0.51% | — | -20.60% | |
| 42 | VERA | Vera Therapeutics Inc | Stock-Other | 0.50% | -0.02% | — | |
| 43 | IMCR 2.5 02-01-30Bond | Immunocore Holdings | Bond | 0.50% | -0.04% | — | |
| 44 | LQDA | Liquidia CORP | Stock-Other | 0.47% | — | — | |
| 45 | DAWNGBX | Day One Biopharmaceuticals I | Stock-Other | 0.46% | -0.94% | EXIT | |
| 46 | PRAX | Praxis Precision Medicines I | Stock-Other | 0.46% | -0.30% | — | |
| 47 | LNTH | Lantheus Holdings Inc | Stock-Healthcare | 0.46% | +0.13% | — | |
| 48 | SVRA | Savara Inc | Stock-Other | 0.44% | — | — | |
| 49 | CGON | Cg Oncology Inc | Stock-Other | 0.41% | — | -0.11% | |
| 50 | ✓ | Establishment Labs Holdings In | Stock-Other | 0.40% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | NBIX | Neurocrine Biosciences Inc | +2% | +72.74% | Add |
| 2 | CNC | Centene CORP | +1.9% | — | Add |
| 3 | BKD | Brookdale Senior Living Inc | +1.5% | — | Add |
| 4 | RVMD | Revolution Medicines Inc | +1.4% | +1.81% | Add |
| 5 | INSM | Insmed Inc | +0.6% | — | Add |
| 6 | CMRXEUR | Chimerix Inc | +0.4% | — | Add |
| 7 | PHVS | Pharvaris N.V. | +0.3% | — | Add |
| 8 | DAWNGBX | Day One Biopharmaceuticals I | +0.1% | +14.05% | Add |
| 9 | CGEM | Cullinan Therapeutics Inc | +0.1% | +14.25% | Add |
| 10 | DCTH | Delcath Systems Inc | +0.1% | — | Add |
| 11 | COGT | Cogent Biosciences Inc | +0.1% | +0.11% | Add |
| 12 | BCRX | Biocryst Pharmaceuticals Inc | 0% | -36.28% | Add |
| 13 | BFLYW | Butterfly Network Inc -cw25 | -0.1% | — | Unchanged |
| 14 | TALK | Talkspace Inc | -0.1% | — | Trim |
| 15 | LRMR | Larimar Therapeutics Inc | -0.1% | — | Add |
| 16 | DYN | Dyne Therapeutics Inc | -0.1% | +86.48% | Add |
| 17 | ANNX | Annexon Inc | -0.2% | — | Unchanged |
| 18 | ALEC | Alector Inc | -0.4% | -1.10% | Unchanged |
| 19 | EWTX | Edgewise Therapeutics Inc | -0.6% | — | Trim |
| 20 | NUVB | Nuvation Bio Inc | -0.6% | +125.37% | Trim |
| 21 | VTRS | Viatris Inc | -0.7% | -0.02% | Add |
| 22 | LUNG | Pulmonx CORP | -1.2% | +23.15% | Add |
| 23 | AHCO | Adapthealth CORP | -1.5% | — | Add |
| 24 | NUVL | Nuvalent Inc-a | — | NEW | New buy |
| 25 | ✓ | Singular Genomics Systems In | — | EXIT | Sold out |
| 26 | NVTA 2 09-01-24Bond | Invitae CORP | — | EXIT | Sold out |
| 27 | ✓ | Caremax Inc | — | EXIT | Sold out |
| 28 | IART 0.5 08-15-25Bond | Integra Lifesciences Hld | — | NEW | New buy |
| 29 | AERI 1.5 10-01-24Bond | Aerie Pharmaceuticals | — | EXIT | Sold out |
| 30 | OSCR | Oscar Health Inc - Class A | — | NEW | New buy |
| 31 | GKOS 2.75 06-15-27Bond | Glaukos CORP | — | EXIT | Sold out |
| 32 | NTRA 2.25 05-01-27Bond | Natera Inc | — | EXIT | Sold out |
| 33 | ✓ | Merus N V | — | NEW | New buy |
| 34 | SPRY | Ars Pharmaceuticals Inc | — | NEW | New buy |
| 35 | BBIO 2.5 03-15-27Bond | Bridgebio Pharma Inc | — | EXIT | Sold out |
| 36 | ACCD 0.5 04-01-26Bond | Accolade Inc | — | NEW | New buy |
| 37 | ALNY 1 09-15-27Bond | Alnylam Pharmaceuticals | — | NEW | New buy |
| 38 | ORGO | Organogenesis Holdings Inc | — | EXIT | Sold out |
| 39 | MIRM 4 05-01-29Bond | Mirum Pharmaceuticals | — | NEW | New buy |
| 40 | NVST 2.375 06-01-25Bond | Envista Holdings CORP | — | EXIT | Sold out |
| 41 | GMED 1 06-01-23Bond | Nuvasive Inc | — | EXIT | Sold out |
| 42 | INDV | Indivior Pharmaceuticals, Inc. | — | NEW | New buy |
| 43 | ALHC | Alignment Healthcare Inc | — | NEW | New buy |
| 44 | UTHR | United Therapeutics CORP | — | NEW | New buy |
| 45 | PFE | Pfizer Inc | — | NEW | New buy |
| 46 | NAMS | NewAmsterdam Pharma Company N.V. | — | NEW | New buy |
| 47 | CPRX | Catalyst Pharmaceuticals Inc | — | NEW | New buy |
| 48 | PODD 0.375 09-01-26Bond | Insulet Corporation | — | EXIT | Sold out |
| 49 | APLS 3.5 09-15-26Bond | Apellis Pharmaceuticals | — | EXIT | Sold out |
| 50 | AFIB | Acutus Medical Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Deerfield Management Company, L.p. reported a total U.S. public equity portfolio value of $9.6B across 123 disclosed positions in Q1 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including NUVL, VTRS, IART 0.5 08-15-25) accounted for 20.7% of total reported equity market value during Q1 2025.
Top New Position Initiated
NUVL
市值: $1.3B
Top Position Liquidated / Trimmed
SINGULAR GENOMICS SYSTEMS IN
前期市值: $250.4M
During Q1 2025, Deerfield Management Company, L.p.'s top holdings by market value included NUVL (25.2%)、VTRS (4.1%)、IART 0.5 08-15-25 (3.4%). The largest single position, NUVL, represented 25.2% of total portfolio value.
In Q1 2025, Deerfield Management Company, L.p. made 197 total portfolio adjustments, initiating 63 new buys, adding to 17 positions, trimming 3 holdings, and fully liquidating 114 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.